小柯机器人

中国科学家发现靶向新冠病毒受体结合位点的中和抗体
2020-05-27 15:30

中国科学院微生物研究所严景华、高福、王奇慧、武汉病毒研究所袁志明、解放军总医院王福生等研究人员合作,发现了一个靶向新冠病毒(SARS-CoV-2)受体结合位点的人源中和抗体。相关论文于2020年5月26日在线发表于《自然》。

研究人员报告了从恢复期COVID-19患者中分离出2种特异性人单克隆抗体(MAb)。CA1和CB6在体外对SARS-CoV-2具有强效的特异性中和活性。此外,CB6在预防和治疗方面均抑制了恒河猴的SARS-CoV-2感染。
 
进一步的结构研究表明,CB6识别与SARS-CoV-2受体结合域(RBD)中的血管紧张素转化酶2(ACE2)结合位点重叠的表位,从而通过空间位阻和直接界面-氨基酸残基竞争来干扰病毒与受体之间的相互作用 。这些结果表明CB6值得进一步的临床转化。
 
附:英文原文

Title: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

Author: Rui Shi, Chao Shan, Xiaomin Duan, Zhihai Chen, Peipei Liu, Jinwen Song, Tao Song, Xiaoshan Bi, Chao Han, Lianao Wu, Ge Gao, Xue Hu, Yanan Zhang, Zhou Tong, Weijin Huang, William Jun Liu, Guizhen Wu, Bo Zhang, Lan Wang, Jianxun Qi, Hui Feng, Fu-sheng Wang, Qihui Wang, George Fu Gao, Zhiming Yuan, Jinghua Yan

Issue&Volume: 2020-05-26

Abstract: An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation.

DOI: 10.1038/s41586-020-2381-y

Source: https://www.nature.com/articles/s41586-020-2381-y

Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:69.504
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html


本期文章:《自然》:Online/在线发表

分享到:

0